abhishreshthaa
Abhijeet S
JN-International Medical Corporation is a U.S. based biopharmaceutical corporation which since 1998 has been focused on developing vaccines and diagnostics for infectious disease for developing countries. This private corporation (formerly known as Jeeri Neotech International, Inc) was founded in 1997 by Dr. Jeeri R. Reddy with the help of Dr. Kelly F. Lechtenberg in a small rural town, Oakland, Nebraska. From there it grew and expanded until in the year 2000 the corporation moved to Omaha, Nebraska. JN-International Medical Corporation (JNI) has overseas business offices and clinical trial centers located in Abidjan, Ivory Coast in Africa and in Kuala Lumpur, Malaysia, with vaccine cold chain facilities in Burkina Faso and Singapore. JNI partners with Global Health Organizations such as the Clinton Global Initiative,[1],the Global Business Coalition, New York[2] President's Malaria Initiative and PEPFAR.[3][4][5] JNI also partners with several other non-profit global health organizations,[6][7] NGOs, local governments and communities in developing countries to address the health issues related to HIV AIDS Malaria Tuberculosis and Bacterial Meningitis that scourges the underserved communities in West Africa, South East Asia and Latin America.
Strengths
* Global presence
* Strong industry standing
* Robust launch portfolio with revenue growth
underscored by the commercialization of
Januvia and Gardasil
* High growth Zetia/Vytorin cardiovascular product franchise
Weaknesses
* Patent expiry for biggest selling product franchise Zocor (mid 2006)
* Weak core portfolio (comprising essentially Zetia/Vytorin) underscored by maturation and migration of key product franchises into expiry portfolio
* Blockbuster growth strategy which closely ties Merck's position in certain therapy markets to just one or two products
Opportunities
* Therapeutic diversification and expansion
into diabetes, oncology and infectious
diseases segments
* Strong potential growth from vaccines
business, driven primarily (but not exclusively) by highly innovative, first-to-market cervical cancer vaccine Gardasil
* Diversification into biologics market via
acquisitions of Abmaxis and GlycoFi
Threats
* Continued exposure to patent expiries and risk of generic competition to key brands across forecast window 2006 to 2012; Fosamax in 2008, Cozaar/Hyzaar in 2009 and Singulair in 2012
* In light of Merck's relatively weak core portfolio and its high generic-exposure expiry portfolio, the company is reliant on considerable sales growth from its launch portfolio, reflecting a higher risk growth strategy versus predominant core-driven growth
Strengths
* Global presence
* Strong industry standing
* Robust launch portfolio with revenue growth
underscored by the commercialization of
Januvia and Gardasil
* High growth Zetia/Vytorin cardiovascular product franchise
Weaknesses
* Patent expiry for biggest selling product franchise Zocor (mid 2006)
* Weak core portfolio (comprising essentially Zetia/Vytorin) underscored by maturation and migration of key product franchises into expiry portfolio
* Blockbuster growth strategy which closely ties Merck's position in certain therapy markets to just one or two products
Opportunities
* Therapeutic diversification and expansion
into diabetes, oncology and infectious
diseases segments
* Strong potential growth from vaccines
business, driven primarily (but not exclusively) by highly innovative, first-to-market cervical cancer vaccine Gardasil
* Diversification into biologics market via
acquisitions of Abmaxis and GlycoFi
Threats
* Continued exposure to patent expiries and risk of generic competition to key brands across forecast window 2006 to 2012; Fosamax in 2008, Cozaar/Hyzaar in 2009 and Singulair in 2012
* In light of Merck's relatively weak core portfolio and its high generic-exposure expiry portfolio, the company is reliant on considerable sales growth from its launch portfolio, reflecting a higher risk growth strategy versus predominant core-driven growth